title: Clinical analysis of stages of HBV infection in 100 cases of lymphoma.
abstract: OBJECTIVE
  HBV infection may cause damage to the immune system and induce lymphomas as a result. Some scholars have indicated that HBsAg(+) reflecting HBV infection may have a relationship with lymphoma development. This study was designed to find out the specific stage of HBV infection which may be related to lymphoma.
  
  
  METHODS
  HBV serum markers, including HBsAg, HBsAb, HBeAg, HBeAb, HBcAb were tested among 100 lymphoma patients and 100 other patients who were diagnosed with non-lymphoma diseases in the First Hospital of Jilin University from 2010.1.1 to 2012.12.31. Three subgroups were established depending on different combinations of HBV serum markers. Subgroup 1 was HBsAg(+) representing the early stage of HBV infection. Subgroup 2 was HbsAb(+) representing convalescence and Subgroup 3 was "HbsAg and HbsAb negative combined with other positive markers" representing the intermediate stage of HBV infection. Chi square tests were used to compare the rates of three subgroups in lymphoma and control groups.
  
  
  RESULTS
  The rates of Subgroup were 13% and 5% respectively, an association between HBsAg and lymphoma being found (P<0.05). There was no difference between rate of Subgroup 2 of lymphoma group (15%) and that of control group (16%). In lymphoma group and control group , the rate of Subgroup 3 was different (12% vs 4%). This evidence was not specific to T cell lymphoma, B cell lymphoma or Hodgkin's lymphoma.
  
  
  CONCLUSIONS
  Among serum markers of HBV, the combination of serum markers representing the early stage and intermediate stage of HBV infection have a relationship with lymphoma. Convalescence from HBV infection appears to have no relationship with lymphoma.
authors.affiliation: Department of Oncology, the First Hospital of Jilin University, the First Hospital of Jilin University, ChangChun, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Tang
authors.forename: Li-Guang
authors.initials: LG
authors.lastname: Sun
authors.forename: Chun-Shui
authors.initials: CS
authors.lastname: Liu
authors.forename: Yu-Ying
authors.initials: YY
authors.lastname: Li
authors.forename: Chun-Hui
authors.initials: CH
authors.lastname: Jin
authors.forename: Dan
authors.initials: D
authors.lastname: Li
authors.forename: Ou
authors.initials: O
authors.lastname: Bai
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D002681:China; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood / Q000276:immunology; D006512:Hepatitis B Core Antigens / Q000097:blood / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000097:blood / Q000276:immunology; D006513:Hepatitis B e Antigens / Q000097:blood / Q000276:immunology; D006515:Hepatitis B virus / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000097:blood* / Q000276:immunology / Q000473:pathology; D006689:Hodgkin Disease / Q000097:blood / Q000821:virology*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000097:blood / Q000821:virology*; D016399:Lymphoma, T-Cell / Q000097:blood / Q000821:virology*; D008297:Male; D008875:Middle Aged; D011795:Surveys and Questionnaires
chemical_list: D014408:Biomarkers, Tumor; D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens